Clinical trials: DENGUE
Dengue
Tetravalent Chimeric Dengue Vaccine Trial
The purpose of this study is to test the safety and immune response to a live attenuated dengue vaccine that could protect people against all 4 types of dengue virus.
- Trial name
- NCT01110551
- Testing
- Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00831012
- Testing
- rDEN3delta30/31-7164
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a…
- Trial name
- NCT05048875
- Testing
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever, Dengue Hemorrhagic Fever
A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children
The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Shock Syndrome
- Trial name
- NCT00468858
- Testing
- T-DEN-Post-Transfection F17, T-DEN-Post-Transfection F19
- Where
- 11 sites in Puerto Rico
- Volunteers
- 636 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue, Chikungunya
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients
Introduction: Dengue and Chikungunya arboviral diseases are considered major public health challenges in tropical regions due to high infection rates and the occurrence of musculoskeletal sequelae that impair strength, balance…
- Trial name
- NCT07600879
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Universidade do Estado do Pará
Dengue Fever
Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever
The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue.
- Trial name
- NCT06877039
- Testing
- Observational studies did not involve any interventions
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
Dengue Fever
Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients
Its a double-blind placebo controlled multicenter study involving confirmed dengue patients who are hospitalized.168 Patients will be enrolled according to specific inclusion \& exclusion criteria and they will be divided into…
- Trial name
- NCT06945679
- Testing
- CPLE
- Where
- Bangladesh
- Volunteers
- 184 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Dengue Hemorrhagic Fever, Awareness
Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing Crises
This study evaluates the awareness of dengue fever and preventive measures among Sudanese people during the war. It assesses knowledge, awareness, implementation of prevention, access to healthcare, community involvement, and the…
- Trial name
- NCT07205848
- Testing
- No intervention
- Where
- Sudan
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Research and Publication office
Dengue Fever
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06665035
- Testing
- TDV
- Where
- 4 sites in Colombia, Thailand
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue, Zika Virus Infection
Applying Wolbachia to Eliminate Dengue
This cluster randomised trial will evaluate the efficacy of Wolbachia-infected Aedes aegytpi mosquitoes in reducing dengue cases in Yogyakarta City, Indonesia
- Conditions
- Dengue, Zika Virus Infection, Chikungunya Fever
- Trial name
- AWED (NCT03055585)
- Testing
- Wolbachia-infected Aedes aegypti mosquitoes, standard practice dengue control
- Where
- Indonesia
- Volunteers
- 8,173 people
- Sponsor
- Gadjah Mada University
Dengue Fever, Dengue Hemorrhagic Fever
Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients
This clinical trial seeks to assess the effectiveness of fresh frozen plasma (FFP) in the treatment of thrombocytopenia in individuals with dengue.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Shock Syndrome
- Trial name
- EFFP-TDP (NCT06642493)
- Testing
- Fresh frozen plasma
- Where
- Bangladesh
- Volunteers
- 300 people
- Sponsor
- Sheikh Hasina National Institute of Burn and Plastic Surgery
Dengue
Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers
Official title: Immunogenicity of an intradermal Qdenga vaccine among healthy volunteers: A pilot study
- Trial name
- NCT06837116
- Testing
- Vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Arbovirus Infections, Zika
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Zika, Dengue, Chikungunya
- Trial name
- VIRIMA (NCT04619823)
- Testing
- Blood sample collection
- Where
- New Caledonia
- Volunteers
- 250 people
- Sponsor
- Institut Pasteur
Dengue Fever, Dengue Haemorrhagic Fever
Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine
Primary objectives: To assess how dengue vaccine efficacy varies across participant subgroups regarding polymorphism in human leukocyte antigen (HLA) alleles of interest.
- Trial name
- NCT02827162
- Where
- Thailand
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects
The aim of the study was to investigate the immunogenicity and safety of CYD dengue vaccine and Tetanus Toxoid (T), Reduced Diphtheria Toxoid (D) and Acellular Pertussis Vaccine Adsorbed (ap) (Tdap) vaccine when both vaccines…
- Trial name
- NCT02992418
- Testing
- CYD Dengue Vaccine, Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed
- Where
- 4 sites in Philippines
- Volunteers
- 688 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Vaccination Strategy Evaluation, Transmission Modeling of Dengue
Understanding the Public Impact on Dengue Vaccination Strategies in Yunnan Province, China: A Dynamic Transmission Modeling Study
This study is a collaboration between the School of Public Health at Fudan University and the Xishuangbanna Center for Disease Control and Prevention in Yunnan Province, China.
- Conditions
- Dengue Vaccination Strategy Evaluation, Transmission Modeling of Dengue, Public Health Impact of Vaccination
- Trial name
- NCT07206784
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Fudan University
Vector Borne Diseases
Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia
Background: Mosquito-borne viruses like dengue cause major illness and death worldwide, particularly in Southeast Asia. When mosquitoes deliver a virus into the skin of humans, they also leave saliva.
- Trial name
- NCT04350905
- Testing
- Mosquito Feeding
- Where
- Cambodia
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
DENGUE
Implementation Research of New Dengue Vector Control Tools
This project will provide new insights concerning how to reduce dengue transmission by means of cost-effective and sustainable implementation strategies of vector control methods.
- Trial name
- NCT00883441
- Testing
- Insecticide treated curtains and insecticide treated covers
- Where
- 2 sites in Thailand, Venezuela
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Dengue Vaccines
Retrospective Analysis of the Second Year of Safety Surveillance of the Qdenga® (TAK-003) Vaccine in Private Vaccination Centers, Including a Sub-analysis of Safety in Adults Over 60 Years of Age
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals aged 4 years and older, with no upper age limit.
- Trial name
- NCT07812142
- Testing
- Tak-003
- Where
- Argentina
- Volunteers
- 94,526 people, healthy volunteers welcome
- Sponsor
- Fundación Vacunar
Dengue Fever
A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
To assess the safety, reactogenicity and immunogenicity of two doses of the dengue vaccine in Flavi-virus antibody-naive children between 6 and 9 years of age.
- Trial name
- NCT00384670
- Testing
- Dengue Vaccine Formulation 17, Licensed Japanese Encephalitis (JE) Vaccine
- Where
- Thailand
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command